Compare ASTI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTI | PLUR |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 33.9M |
| IPO Year | 2014 | 2001 |
| Metric | ASTI | PLUR |
|---|---|---|
| Price | $4.19 | $3.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $12.00 |
| AVG Volume (30 Days) | ★ 1.6M | 4.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.23 | 10.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,398,149.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 163.25 | ★ 309.82 |
| 52 Week Low | $1.40 | $2.82 |
| 52 Week High | $9.87 | $6.10 |
| Indicator | ASTI | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 54.33 |
| Support Level | $3.34 | $3.14 |
| Resistance Level | $4.68 | $3.85 |
| Average True Range (ATR) | 0.63 | 0.14 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 9.25 | 41.79 |
Ascent Solar Technologies Inc is a solar technology company that manufactures and sells photovoltaic (PV) solar modules that are flexible, durable, and possess attractive power to weight and power to area performance. Its technology provides renewable power solutions to high-value production and specialty solar markets where traditional rigid solar panels are not suitable, including space power beaming, aerospace, satellites, near earth orbiting vehicles, fixed wing unmanned aerial vehicles (UAV), aquatic, terrestrial, and other weight-sensitive markets with transformational high quality, value added product applications. It operates in single PV segment that sells PV products and engineering services and currently, is selling it in North America.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.